<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910362</url>
  </required_header>
  <id_info>
    <org_study_id>CP-02</org_study_id>
    <nct_id>NCT02910362</nct_id>
  </id_info>
  <brief_title>Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines</brief_title>
  <official_title>Intra-surgical Evaluation of CATS Tonometer Prism and AMO Versus Alcon Phacoemulsification Machines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intuor Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Intuor Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the dynamic real-time intraocular pressure (IOP) in the anterior
      chamber during standard phacoemulsification surgery.

      What is known:

        -  Fluidics control is determined to be one of the primary drivers of physician decision
           making in choosing phacoemulsification equipment.

        -  Active pressure system fluidic control has a perceived and possibly real (based upon
           recent literature) improvement in intra-cameral IOP stability and reduced pressure
           fluctuations.

        -  Improved fluidics can allow for reduced dynamic IOP fluctuations, in-the-bag positioned
           phaco tip, and intra-cameral fluid flow all of which will likely improve corneal health
           post-operatively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Comparative IOP Stability Between Abbott and Alcon Phacoemulsification Equipment.</measure>
    <time_frame>intraoperative</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>Alcon phacoemulsification equipment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cataract surgery performed with the Alcon phacoemulsification equipment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMO phacoemulsification equipment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cataract surgery with the AMO phacoemulsification equipment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alcon phacoemulsification equipment</intervention_name>
    <description>cataract surgery with Alcon phacoemulsification equipment.</description>
    <arm_group_label>Alcon phacoemulsification equipment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMO phacoemulsification equipment</intervention_name>
    <description>cataract surgery with AMO phacoemulsification equipment.</description>
    <arm_group_label>AMO phacoemulsification equipment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Age 18 or greater

               -  Bilateral cataracts for which phacoemulsification extraction and posterior IOL
                  implantation has been planned for both eyes

               -  Subjects able to give informed consent

               -  Nuclear Sclerotic cataract graded 2+ or 3+

               -  Naturally dilated pupil size (in dim light) &gt; 4.0 mm (with no dilation
                  medications) for both eyes

               -  Preoperative corneal astigmatism of 2.5 D or less

               -  Ages between 55 and 80

               -  Availability, willingness, and sufficient cognitive awareness to comply with
                  examination procedures

        Exclusion Criteria:

          -  • Uncontrolled systemic disease that in the opinion of the Investigator would put the
             subject's heath at risk

               -  Intraoperative complications

               -  Subjects with only one functional eye

               -  Those with one eye having poor or eccentric fixation

               -  Mild or severe cataracts, predominantly posterior subcapsular cataracts

               -  High corneal astigmatism (i.e. those eyes displaying an oval contact image)

               -  Those with corneal scarring or who have had corneal surgery including corneal
                  laser surgery

               -  Microphthalmos

               -  Buphthalmos

               -  Severe Dry eyes

               -  Blepharospasm

               -  Nystagmus

               -  Keratoconus

               -  Any other corneal or conjunctival pathology or infection.

               -  Central corneal thickness greater than 0,600 mm or less than 0,500 mm (2 standard
                  deviations about the human mean)

               -  Acute or chronic disease or illness that would increase risk or confound study
                  results (e.g. diabetes mellitus, immunocompromised, etc.)

               -  Uncontrolled systemic or ocular disease

               -  History of ocular trauma or prior ocular surgery

               -  Fuchs Dystrophy

               -  Subjects who may be expected to require retinal laser treatment or other surgical
                  intervention, including LRI's

               -  Capsule or zonular abnormalities that may affect postoperative centration or tilt
                  of the lens (e.g. pseudoexfoliation syndrome)

               -  Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or
                  pupils that do not dilate at least 4.0 mm under mesopic/scotopic conditions)

               -  Contact lens usage within 6 months for PMMA contacts lenses, 1 month for gas
                  permeable lenses or 1 week for extended-wear and daily-wear soft contact lens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean McCafferty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona Eye Consultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Eye Consultants</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <results_first_submitted>April 25, 2017</results_first_submitted>
  <results_first_submitted_qc>June 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2017</results_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipivefrin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From September 2016 until December 2016, 30 eyes of 15 patients were enrolled at Arizona Eye Consultants clinic</recruitment_details>
      <pre_assignment_details>Patients were included in the study based upon meeting inclusion criteria and not meeting exclusion criteria. Eyes were randomized to either group based upon a random number generator.
One participant from the &quot;Alcon Phacoemulsification Equipment&quot; Arm had one eye counted for the &quot;AMO Phacoemulsification Equipment&quot; Arm</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alcon Phacoemulsification Equipment</title>
          <description>cataract surgery performed with the Alcon phacoemulsification equipment
Alcon phacoemulsification equipment: cataract surgery with Alcon phacoemulsification equipment.</description>
        </group>
        <group group_id="P2">
          <title>AMO Phacoemulsification Equipment</title>
          <description>cataract surgery with the AMO phacoemulsification equipment
AMO phacoemulsification equipment: cataract surgery with AMO phacoemulsification equipment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alcon Phacoemulsification Equipment</title>
          <description>cataract surgery performed with the Alcon phacoemulsification equipment
Alcon phacoemulsification equipment: cataract surgery with Alcon phacoemulsification equipment.</description>
        </group>
        <group group_id="B2">
          <title>AMO Phacoemulsification Equipment</title>
          <description>cataract surgery with the AMO phacoemulsification equipment
AMO phacoemulsification equipment: cataract surgery with AMO phacoemulsification equipment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>eyes</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="8"/>
                    <measurement group_id="B2" value="66" spread="8"/>
                    <measurement group_id="B3" value="66" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine Comparative IOP Stability Between Abbott and Alcon Phacoemulsification Equipment.</title>
        <time_frame>intraoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alcon Phacoemulsification Equipment</title>
            <description>cataract surgery performed with the Alcon phacoemulsification equipment
Alcon phacoemulsification equipment: cataract surgery with Alcon phacoemulsification equipment.</description>
          </group>
          <group group_id="O2">
            <title>AMO Phacoemulsification Equipment</title>
            <description>cataract surgery with the AMO phacoemulsification equipment
AMO phacoemulsification equipment: cataract surgery with AMO phacoemulsification equipment.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Comparative IOP Stability Between Abbott and Alcon Phacoemulsification Equipment.</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="1.05"/>
                    <measurement group_id="O2" value="2.30" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alcon Phacoemulsification Equipment</title>
          <description>cataract surgery performed with the Alcon phacoemulsification equipment
Alcon phacoemulsification equipment: cataract surgery with Alcon phacoemulsification equipment.</description>
        </group>
        <group group_id="E2">
          <title>AMO Phacoemulsification Equipment</title>
          <description>cataract surgery with the AMO phacoemulsification equipment
AMO phacoemulsification equipment: cataract surgery with AMO phacoemulsification equipment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small population size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sean McCafferty, MD</name_or_title>
      <organization>Arizona Eye Consultants</organization>
      <phone>(520) 791-7401</phone>
      <email>sjmccafferty66@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

